Furthermore, the expression of MEG3 was tightly correlated with the expression of Schlafen-5 (SLFN5), and overexpression of MEG3 ameliorated EMT in highly invasive breast cancer cells by modulating SLFN5 expression via MEG3/miR-146b-5p/SLFN5 axis (Gu et al., 2022). This evidence concerns the gene MEG3 and breast carcinoma.